全文获取类型
收费全文 | 3371篇 |
免费 | 342篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 139篇 |
妇产科学 | 69篇 |
基础医学 | 412篇 |
口腔科学 | 47篇 |
临床医学 | 321篇 |
内科学 | 661篇 |
皮肤病学 | 35篇 |
神经病学 | 382篇 |
特种医学 | 176篇 |
外科学 | 357篇 |
综合类 | 144篇 |
一般理论 | 2篇 |
预防医学 | 411篇 |
眼科学 | 101篇 |
药学 | 261篇 |
1篇 | |
肿瘤学 | 198篇 |
出版年
2022年 | 21篇 |
2021年 | 49篇 |
2020年 | 26篇 |
2019年 | 49篇 |
2018年 | 68篇 |
2017年 | 39篇 |
2016年 | 43篇 |
2015年 | 52篇 |
2014年 | 77篇 |
2013年 | 108篇 |
2012年 | 143篇 |
2011年 | 161篇 |
2010年 | 97篇 |
2009年 | 98篇 |
2008年 | 126篇 |
2007年 | 136篇 |
2006年 | 148篇 |
2005年 | 123篇 |
2004年 | 111篇 |
2003年 | 129篇 |
2002年 | 91篇 |
2001年 | 113篇 |
2000年 | 96篇 |
1999年 | 96篇 |
1998年 | 69篇 |
1997年 | 80篇 |
1996年 | 77篇 |
1995年 | 71篇 |
1994年 | 60篇 |
1993年 | 65篇 |
1992年 | 72篇 |
1991年 | 63篇 |
1990年 | 70篇 |
1989年 | 76篇 |
1988年 | 68篇 |
1987年 | 49篇 |
1986年 | 41篇 |
1985年 | 62篇 |
1984年 | 56篇 |
1983年 | 46篇 |
1982年 | 41篇 |
1981年 | 44篇 |
1980年 | 35篇 |
1978年 | 26篇 |
1977年 | 32篇 |
1976年 | 34篇 |
1975年 | 28篇 |
1974年 | 27篇 |
1971年 | 22篇 |
1970年 | 21篇 |
排序方式: 共有3722条查询结果,搜索用时 0 毫秒
61.
几种中西药抗人实验模拟运动病效果观察 总被引:1,自引:0,他引:1
目的 :选用中药“治晕灵”的主要成分生姜、明天麻等六味草药煎成汤剂、或半量汤剂配西药脑益嗪、山莨菪碱各1 4临床常用量配成复方中西药制剂 ,与目前常用抗晕药晕海宁等中、西药的药效进行比较 ,看中药制剂或中西药复方制剂是否具有较好的抗运动病效果。方法 :选 7名敏感被试者 (女性 ,19~ 2 1岁 ) ,用旋转刺激诱发运动病至出现恶心。按拉丁方设计 ,与安慰剂 (淀粉 10 0mg)及晕海宁 (5 0mg)进行对比 ,分别观察了生姜合剂 (30ml)、晕可平 (30ml)、山莨菪碱 (10mg)、脑益嗪 (2 5mg)及上述复方中西药制剂口服后的运动病耐力。结果 :与安慰剂比较 ,晕海宁、山莨菪碱、脑益嗪、晕可平、生姜合剂、复方中西药制剂分别使运动病耐力提高 5 .4%、7.5 %、5 .9%、7.4%、32 .3 %、2 0 .4% ;生姜合剂效果较优 ,除口服时有辛辣味外 ,无明显的副作用。复方中西药制剂各成分未显示协同作用 ,而只是简单的作用相加。结论 :生姜合剂具有较好的抗运动病作用 相似文献
62.
Non-invasive detection of fecal protein kinase C betaII and zeta messenger RNA: putative biomarkers for colon cancer 总被引:2,自引:0,他引:2
Davidson LA; Aymond CM; Jiang YH; Turner ND; Lupton JR; Chapkin RS 《Carcinogenesis》1998,19(2):253-257
We have developed a non-invasive method utilizing feces, containing
sloughed colonocytes, as a sensitive technique for detecting diagnostic
colonic biomarkers. In this study, we used the rat colon carcinogenesis
model to determine if changes in fecal protein kinase C (PKC) expression
have predictive value in monitoring the neoplastic process. Weanling rats
were injected with saline or azoxymethane (AOM) and 36 weeks later fecal
samples and mucosa were collected, poly A+ RNA isolated, and quantitative
RT-PCR performed using primers to PKC betaII and zeta. Fecal PKC betaII and
zeta mRNA levels were altered by the presence of a tumor, with
tumor-bearing animals having a 3-fold higher (P < 0.05) PKC betaII
expression as compared with animals without tumors. In addition,
AOM-injection increased mucosal PKC betaII mRNA expression compared with
saline controls. No effect of tumor incidence on mucosal PKC betaII
expression was observed. In contrast, fecal PKC zeta expression was
2.5-fold lower (P < 0.05) in animals injected with azoxymethane versus
saline. Since tumor incidence exerts a reciprocal effect on fecal PKC
betaII and zeta mRNA expression, data were also expressed as the ratio
between PKC betaII and zeta. The isozyme ratio was strongly related to
tumor incidence, i.e. ratio for animals with tumors was 2.18 +/- 1.25,
animals without tumors was 0.50 +/- 0.16, P = 0.025. We demonstrate that
the expression of fecal PKC betaII and zeta may serve as a noninvasive
marker for development of colon tumors. A sensitive technique for the
detection of colon cancer is of importance since early diagnosis can
substantially reduce mortality.
相似文献
63.
男性与女性糖尿病患者致死性冠心病的额外危险:37个前瞻性队列研究的汇总分析 总被引:6,自引:0,他引:6
目的:估计男性和女性糖尿病患者致死性冠心病的相对危险。设计:前瞻性队列研究的汇总分析。数据来源:自1966年至2005年3月间Embase和Medline确认并发表的研究,加上源自亚太队列研究协作组的研究,采用正文词组与MeSH主题词相结合的策略进行检索。综述方法:对入选研究的要求为报告有或无糖尿病的男性与女性致死性冠心病的相对危险比较的估计值。如果对估计值仅做年龄调整(而其它因素来经调整——泽者注),则将该研究排除在外。结果:总共纳入37项2型糖尿病和致死性冠心病的研究,涉及447064例患者。糖尿病患者的致死性冠心病发生率显著高于非糖尿病患者(5.4%比1.6%)。与无糖尿病者相比,糖尿病患者发生致死性冠心病的总的相对危险,女性为3.50,95%可信区间为2.70~4.53,显著高于男性患者(2.06,95%可信区间1.81~2.34)。在除外8项仅根据年龄调整的研究后,两性之间危险的差异大大减小,但仍然具有极显著统计学意义。汇集29项经多因素调整估计值的研究,总的相对危险比(女性比男性)为1.46(1.14~1.88)。结论:糖尿病相关的致死性冠心病相对危险,女性比男性高出50%。这种额外的冠心病危险可以通过女性糖尿病患者具有更多不利的心血管危险因素特点以及倾向于对男性患者更注重治疗的可能偏差来解释。 相似文献
64.
In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate 总被引:5,自引:0,他引:5
Lippiello L Woodward J Karpman R Hammad TA 《Clinical orthopaedics and related research》2000,(381):229-240
Supplements of glucosamine hydrochloride, low molecular weight chondroitin sulfate, and manganese ascorbate were tested separately and in combination for their ability to retard progression of cartilage degeneration in a rabbit instability model of osteoarthrosis. Computerized quantitative histologic evaluation of safranin O stained sections of the medial femoral condyles measured the grade and extent of tissue involvement of lesions. Severe lesions (Mankin grade greater than 7) were absent in all animals supplemented with a dietary mixture of glucosamine, chondroitin sulfate, and manganese ascorbate. Total linear involvement (mm of lesioned surface) and total grade (mean grade x number of lesions per animal) were reduced significantly in animals given the combination compared with controls (59% and 74% respectively). Animals supplemented with glucosamine, chondroitin sulfate, or manganese ascorbate alone had less moderate and severe tissue involvement than controls but not to the extent of the combined group. In vitro, a combination of glucosamine hydrochloride and chondroitin sulfate acted synergistically in stimulating glycosaminoglycan synthesis (96.6%). Chondroitin sulfate and manganese ascorbate but not glucosamine were effective in inhibiting degradative enzyme activity. These data suggest that the disease modifying effect (the ability to retard progression of cartilage degeneration) of a mixture of glucosamine, chondroitin sulfate, and manganese ascorbate is more efficacious than either agent alone. 相似文献
65.
66.
67.
Joseph Driver Samantha E Hoffman Sherwin Tavakol Eleanor Woodward Eduardo A Maury Varun Bhave Noah F Greenwald Farshad Nassiri Kenneth Aldape Gelareh Zadeh Abrar Choudhury Harish N Vasudevan Stephen T Magill David R Raleigh Malak Abedalthagafi Ayal A Aizer Brian M Alexander Keith L Ligon David A Reardon Patrick Y Wen Ossama Al-Mefty Azra H Ligon Adrian M Dubuc Rameen Beroukhim Elizabeth B Claus Ian F Dunn Sandro Santagata Wenya Linda Bi 《Neuro-oncology》2022,24(5):796
BackgroundMeningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management.MethodsWe evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms.ResultsWe developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score.ConclusionWe propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients. 相似文献
68.
69.
70.
Puneeth Iyengar Eric A. Strom Yu‐Jing Zhang Gary J. Whitman Benjamin D. Smith Wendy A. Woodward Tse‐Kuan Yu Thomas A. Buchholz 《The oncologist》2012,17(11):1402-1408
Assessment of the regional lymphatics is important for accurate staging and treatment of breast cancer patients. We sought to determine the role of regional ultrasound in providing clinically relevant information. We retrospectively analyzed data from patients who were treated curatively in 1996–2006 at The University of Texas MD Anderson Cancer Center for clinical stage III breast cancer. We compared differences in regional lymph node staging based on ultrasound versus mammography and physical examination in the 865 of 1,200 patients who had external-beam radiation as part of their treatment and regional ultrasound studies as part of their initial evaluation. Ultrasound uniquely identified additional lymph node involvement beyond the level I or II axilla in 37% of the patients (325 of 865), leading to a change in clinical nodal stage. Ninety-one percent of these abnormalities that could be biopsied (266 or 293) were confirmed to contain disease. The sites of additional regional nodal disease were: infraclavicular disease, 32% (275 of 865); supraclavicular disease, 16% (140 of 865); and internal mammary disease, 11% (98 of 865). All patients with involvement in the extra-axillary regional nodal basins received a radiation boost to the involved areas ≥10 Gy. Thus, over one third of patients with advanced breast cancer had their radiation plan altered by the ultrasound findings. Regional ultrasound evaluation in patients with advanced breast cancer commonly revealed abnormalities within and beyond the axilla, which changed the clinical stage of disease and the radiation treatment strategy. Therefore, regional ultrasound is beneficial in the initial staging evaluation for such patients. 相似文献